Saro H Armenian1, Luc Mertens2, Cameron Slorach2, Kalyanasundaram Venkataraman3, Kristen Mascarenhas1, Nitya Nathwani4, F Lennie Wong1, Stephen J Forman4, Smita Bhatia5. 1. Department of Population Sciences, City of Hope, Duarte, California. 2. Department of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 3. Department of Cardiology, City of Hope, Duarte, California. 4. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. 5. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND: Anthracycline-related heart failure is a leading cause of morbidity in survivors of adult-onset lymphoma. There is a paucity of information on screening for late-occurring preclinical disease, which, in turn, has limited guidelines for early detection and intervention. The objectives of this study were to examine the prevalence and risk of cardiac dysfunction, as measured by echocardiography (abnormal left ventricular systolic/diastolic function or strain), in lymphoma survivors who received treatment with anthracyclines and to evaluate the diagnostic yield of blood biomarkers in the asymptomatic setting. METHODS: Lymphoma survivors who underwent hematopoietic cell transplantation (HCT) (n = 78) or received conventional therapy (non-HCT; n = 77) were compared with each other and with a group of matched controls (n = 51); the study was limited to lymphoma survivors who were >5 years from diagnosis. RESULTS: At a median follow-up of 9.4 years after diagnosis, 1 in 5 (20.6 %) lymphoma survivors had cardiac dysfunction; the odds of having cardiac dysfunction were 6.6-fold greater (odds ratio [OR], 6.6; P = .01) among lymphoma survivors compared with matched controls. There was a dose-dependent risk of cardiac dysfunction according to the cumulative anthracycline dose (controls [referent group], 1-249 mg/m2 [OR, 4.7; P = .05], and ≥250 mg/m2 [OR, 7.6; P < .01]), but there was no difference in the prevalence of cardiac dysfunction between conventionally treated and HCT survivors. The diagnostic accuracy of cardiac blood biomarkers in the asymptomatic setting was quite poor. CONCLUSIONS: In these long-term survivors, there was a high rate of cardiac dysfunction that was independent of HCT status. The growing number of lymphoma survivors makes it imperative to identify reliable and cost-effective strategies to decrease the burden of heart failure in this population. Cancer 2018;124:850-7.
BACKGROUND:Anthracycline-related heart failure is a leading cause of morbidity in survivors of adult-onset lymphoma. There is a paucity of information on screening for late-occurring preclinical disease, which, in turn, has limited guidelines for early detection and intervention. The objectives of this study were to examine the prevalence and risk of cardiac dysfunction, as measured by echocardiography (abnormal left ventricular systolic/diastolic function or strain), in lymphoma survivors who received treatment with anthracyclines and to evaluate the diagnostic yield of blood biomarkers in the asymptomatic setting. METHODS:Lymphoma survivors who underwent hematopoietic cell transplantation (HCT) (n = 78) or received conventional therapy (non-HCT; n = 77) were compared with each other and with a group of matched controls (n = 51); the study was limited to lymphoma survivors who were >5 years from diagnosis. RESULTS: At a median follow-up of 9.4 years after diagnosis, 1 in 5 (20.6 %) lymphoma survivors had cardiac dysfunction; the odds of having cardiac dysfunction were 6.6-fold greater (odds ratio [OR], 6.6; P = .01) among lymphoma survivors compared with matched controls. There was a dose-dependent risk of cardiac dysfunction according to the cumulative anthracycline dose (controls [referent group], 1-249 mg/m2 [OR, 4.7; P = .05], and ≥250 mg/m2 [OR, 7.6; P < .01]), but there was no difference in the prevalence of cardiac dysfunction between conventionally treated and HCT survivors. The diagnostic accuracy of cardiac blood biomarkers in the asymptomatic setting was quite poor. CONCLUSIONS: In these long-term survivors, there was a high rate of cardiac dysfunction that was independent of HCT status. The growing number of lymphoma survivors makes it imperative to identify reliable and cost-effective strategies to decrease the burden of heart failure in this population. Cancer 2018;124:850-7.
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2009-04-14 Impact factor: 24.094
Authors: M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie Journal: J Clin Oncol Date: 1984-02 Impact factor: 44.544
Authors: Frederika A van Nimwegen; Michael Schaapveld; Cécile P M Janus; Augustinus D G Krol; Eefke J Petersen; John M M Raemaekers; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald Journal: Eur J Heart Fail Date: 2008-08-29 Impact factor: 15.534
Authors: Annelies M C Mavinkurve-Groothuis; Jacqueline Groot-Loonen; Louise Bellersen; Milanthy S Pourier; Ton Feuth; Jos P M Bökkerink; Peter M Hoogerbrugge; Livia Kapusta Journal: Pediatr Blood Cancer Date: 2009-05 Impact factor: 3.167
Authors: Saro H Armenian; Sarah K Gelehrter; Tabitha Vase; Rajkumar Venkatramani; Wendy Landier; Karla D Wilson; Claudia Herrera; Leah Reichman; John-David Menteer; Leo Mascarenhas; David R Freyer; Kalyanasundaram Venkataraman; Smita Bhatia Journal: Clin Cancer Res Date: 2014-06-19 Impact factor: 12.531
Authors: Shelby N Hader; Natalya Zinkevich; Laura E Norwood Toro; Alison J Kriegel; Amanda Kong; Julie K Freed; David D Gutterman; Andreas M Beyer Journal: Am J Physiol Heart Circ Physiol Date: 2019-08-09 Impact factor: 4.733
Authors: Daniel A Cehic; Aaron L Sverdlov; Bogda Koczwara; Jon Emery; Doan T M Ngo; Elysia Thornton-Benko Journal: Curr Treat Options Oncol Date: 2021-10-21
Authors: Jan M Leerink; Helena J H van der Pal; Leontien C M Kremer; Elizabeth A M Feijen; Paola G Meregalli; Milanthy S Pourier; Remy Merkx; Louise Bellersen; Elvira C van Dalen; Jacqueline Loonen; Yigal M Pinto; Livia Kapusta; Annelies M C Mavinkurve-Groothuis; Wouter E M Kok Journal: JACC CardioOncol Date: 2021-03-16
Authors: Ellen K Chang; Dayana Chanson; Jennifer Berano Teh; Aleksi Iukuridze; Kelly Peng; Stephen J Forman; Ryotaro Nakamura; F Lennie Wong; LiYing Cai; Saro H Armenian Journal: J Clin Oncol Date: 2021-01-08 Impact factor: 44.544
Authors: Shruti Rajesh Patel; Joerg Herrmann; Robert A Vierkant; Janet E Olson; Fergus J Couch; Antonious Hazim; Jeff A Sloan; Charles L Loprinzi; Kathryn J Ruddy Journal: J Clin Med Date: 2021-07-27 Impact factor: 4.241